Highest-materiality recent filing
Bionano Genomics hires Alex Hastie, Ph.D., as Chief Scientific Officer effective July 20, 2026
Hastie returns after 14 years at Bionano as a foundational figure in optical genome mapping (OGM) technology.
Bionano Genomics CMO Alka Chaubey resigns effective July 5, 2026
Alka Chaubey, Ph.D. resigned as Chief Medical Officer on June 2, 2026.
Bionano retires all $20M senior secured convertible debentures, eliminating secured debt
Retired $20M in senior secured convertible debentures using cash on hand on May 26, 2026.
Bionano Genomics stockholders elect Luderer and Vuori as directors; pay vote and auditor ratified
Elected Albert Luderer (847,601 for) and Kristiina Vuori (867,474 for) as Class II directors for three-year terms.
Bionano Q1 revenue $6.7M (+4% YoY); gross margin 49%; positive coding updates
Total revenue $6.7M (+4% vs $6.5M Q1 2025); consumables revenue $3.9M (+20%).
Bionano Genomics CEO Erik Holmlin terminated; Chairman Al Luderer named interim CEO
CEO Erik Holmlin terminated effective May 5, 2026; will serve as advisor under consulting agreement.
Bionano Q4 2025 revenue $8.0M (-3% YoY); FY revenue $28.5M (-7%)
Q4 2025 revenue $8.0M vs $8.2M Q4 2024; consumables/software revenue down 1%.
Bionano reports preliminary Q4/FY 2025 revenue down 2-8% YoY; cash $29.6M
Total Q4 revenue $7.8-8.0M, down 2-4% YoY; full-year $28.4-28.6M, down 7-8%.
Bionano Q3 revenue $7.4M (+21% YoY); raises FY 2025 OGM install guidance
Total revenue $7.4M, up 21% from $6.1M in Q3 2024; consumables/software revenue +15%.
Bionano Genomics closes $10M public offering of 5M shares and warrants
Gross proceeds of $10M from sale of 5M shares and Series E/F warrants to purchase up to 10M shares.
Bionano Q2 2025 revenue $6.7M (-13% YoY); gross margin 52% vs 33%; flowcell sales +17%
Total revenue $6.7M (-13% YoY); prior year included $0.7M discontinued clinical services; adjusted consumables/software/services up 11%.
Bionano Genomics corrects vote counts for Proposals 3 and 4; results unchanged
Corrected Broker Non-Votes for Proposal 3 from 769,744 to 0; no impact on ratification of BDO USA as auditor.
Kristiina Vuori appointed to Audit Committee effective June 10, 2025.
Bionano Q1 revenue $6.5M, down 26% YoY; FY2025 guidance $26-30M
Q1 revenue $6.5M vs $8.8M YoY, down 26%; GAAP gross margin improved to 46% from 32%.
Bionano Genomics Q4 revenue down 24% YoY to $8.2M; full-year revenue $30.8M, down 15%
Q4 2024 revenue $8.2M vs $10.8M in Q4 2023, decline driven by discontinued clinical services; core product revenue 1% higher for full year.
Bionano Genomics enters new $75M ATM sales agreement with H.C. Wainwright, replacing Cowen facility
Terminated prior Cowen sales agreement effective Feb 14, 2025; suspended offering Feb 4.
Bionano Genomics terminates $200M ATM equity facility with Cowen, effective Feb 14, 2025
Terminated Sales Agreement with Cowen and Company effective Feb 14, 2025.
Bionano Genomics effects 1-for-60 reverse stock split effective Jan 24, 2025
Reverse stock split at ratio 1:60, effective 5:00 p.m. ET on January 24, 2025.
Bionano Genomics stockholders approve reverse stock split (1:25-1:75) and warrant share issuance
At Jan 15 special meeting, stockholders approved issuance of up to 19,762,226 shares upon exercise of Series C/D warrants.
Bionano reports preliminary Q4 rev $7.9-8.1M (down ~25% YoY); FY rev $30.5-30.7M (down ~15%)
Preliminary Q4 2024 revenue $7.9-8.1M, down ~25% from Q4 2023 due to discontinued clinical service products.
Bionano Genomics raises $10M in registered direct offering of ~39.7M shares and warrants
Aggregate gross proceeds of ~$10M from sale of 22.9M common shares and 16.78M pre-funded warrants at $0.252/unit.
Amendment defers December 2024 redemption; monthly payments cut from $1M to $500k for Jan-Jul 2025, then rise to $1.375M from Aug 2025.
Bionano Genomics stockholders approve issuance of up to 35M shares upon warrant exercise
Vote passed: 22.9M for, 6.2M against, 1.4M abstentions, no broker non-votes.
Bionano Q3 revenue $6.1M (-35% YoY); GAAP gross margin -139% on $9.8M impairment; cash burn down
Revenue $6.1M (-35% YoY); core product/software sales $6.6M offset by $0.5M receivable write-down from discontinued clinical services.
Issued 9,881,113 shares of common stock and Series C/D warrants to purchase up to 9,881,113 shares each at $0.3039 per share.
Bionano lowers Q3 revenue guidance to $6.5-6.8M from $7.9-8.9M; cash $23.3M
Preliminary Q3 revenue $6.5-6.8M, down from prior guidance of $7.9-8.9M.
Bionano cuts workforce 45%, lowers revenue guidance to $32-36M, CFO departs
Reduction of ~84 employees (45% of workforce); expects $25-30M annual cost savings starting Q4 2024.
Bionano Q2 revenue $7.8M (-10% YoY); FY2024 guidance $36-40M; retires $15.3M notes
Q2 2024 revenue $7.8M, down 10% YoY; GAAP gross margin 33% vs 27% in Q2 2023.
Bionano Genomics receives Nasdaq notice for bid price below $1.00; 180-day cure period
Nasdaq notified Bionano on July 12, 2024 that its stock closed below $1.00 for 30 consecutive trading days.
17.5M shares/equivalents sold at $0.571/share for gross proceeds of ~$10M.
Elected Christopher Twomey, Yvonne Linney, and Aleksander Rajkovic as Class III directors until 2027.
Bionano raises $18M via convertible debt, retires High Trail Note, warns of going concern
Issued $20M principal senior secured convertible debentures (11% interest, due 2026) plus 2.25M shares for $18M gross proceeds.
Bionano Q1 revenue $8.8M (+18% YoY); cash burn down 41% YoY; restructuring charges $4.6M
Q1 2024 revenue $8.8M, +18% YoY; GAAP gross margin 32% vs 28% in Q1 2023.
Bionano Genomics files $8.7M registered direct offering of common stock and warrants
Offering includes 6,536,682 common shares, pre-funded warrants for 2,196,944 shares, and warrants for 8,733,626 shares.
Issues 8.73M shares (or equivalents) and warrants to purchase 8.73M shares at $1.02; exercise price $1.02, 5-year term.
Bionano Genomics reports Q4 revenue $10.7M (+30% YoY), announces 34-39% workforce reduction
Q4 2023 revenue $10.7M, FY 2023 revenue $36.1M, both up 30% YoY.
Bionano amends convertible debt deal, redeems $27.7M of notes, cuts liquidity covenant to $25M
Redeems entire $17M outstanding principal of Initial Private Placement Note at 115% for $19.55M; plus $1M increase to retirement fee.
Bionano prelim Q4 rev $10.4-10.7M (+27-30% YoY); OGM base 326 (+36%)
Prelim Q4 2023 rev $10.4-10.7M vs $8.2M Q4 2022; FY rev $35.8-36.1M (+29-30%).
Bionano Genomics files updated legal opinion to increase ATM shares capacity to 149M
Updated legal opinion from Cooley LLP covers up to 149M shares under ATM sales agreement with Cowen.
Bionano Q3 revenue $9.3M (+29% YoY); $80M convertible notes completed; $33M cost savings plan
Q3 revenue $9.3M, +29% YoY; GAAP gross margin 30% vs 25% YoY; non-GAAP operating expense $31.8M.
Entered securities purchase agreement to issue $45M registered and $35M private senior secured convertible notes due 2025; warrants to buy up to 21.66M shares at $3.1855.
Bionano Genomics appoints Gülsen Kama as CFO effective September 11, 2023; Chris Stewart resigns
Kama's base salary set at $460,000/year with 55% target bonus; receives option for 106,000 shares vesting over 4 years.
Bionano Genomics Q2 revenue up 30% to $8.7M; flowcell sales more than double YoY
Q2 2023 revenue $8.7M, +30% YoY; GAAP gross margin 27% vs 22%.
Bionano Genomics effects 1-for-10 reverse stock split, effective August 4, 2023
Reverse stock split at ratio 1:10 effective 5:00 p.m. ET on August 4, 2023; trading on split-adjusted basis begins August 7, 2023.
Bionano Genomics updates legal opinion to cover up to 49M shares under ATM facility
Filed updated legal opinion with SEC covering sale of up to 49M shares of common stock under existing ATM facility with Cowen.
Bionano shareholders approve reverse split authorization; directors elected
Stockholders approved a reverse stock split at a ratio between 1-for-5 and 1-for-10 at board's discretion.
Bionano Genomics receives Nasdaq delisting notice for bid price below $1.00
Nasdaq notified Bionano on May 30, 2023 that its common stock bid price closed below $1.00 for 30 consecutive days.
Bionano Q1 revenue $7.4M (+30% YoY); announces ~$20M cost reduction plan including layoffs
GAAP gross margin improved to 28% from 15% YoY; non-GAAP gross margin 30%.
Bionano preliminary Q1 revenue $7.3-7.5M, up 28-32% YoY; withdraws CPT code applications
Preliminary Q1 revenue $7.3-7.5M, representing 10th consecutive YoY growth quarter.
Bionano issues Series A Preferred with 3B votes to Board Chair to facilitate reverse stock split
Issued one share of Series A Preferred to Chair David Barker for $100; share carries 3,000,000,000 votes.
On June 2, 2026, Alka Chaubey, Ph.D. resigned as Chief Medical Officer of Bionano Genomics, Inc. (the “Company”) effective July 5, 2026.
As of the Effective Date, the Board appointed Albert A. Luderer, Ph.D., who currently serves as the Company’s Chairman of the Board, as the Company’s Interim Chief Executive Officer.
On May 5, 2026 (the “Effective Date”), Bionano Genomics, Inc. (the “Company”) R. Erik Holmlin, Ph.D. was terminated as the Company’s President and Chief Executive Officer, effective immediately.
On September 4, 2024, R. Erik Holmlin, Ph.D., President and Chief Executive Officer of the Company, was appointed by the Board of Directors (the “Board”) of the Company to serve as the principal financial officer of the Company, effective September 18, 2024
the role of our Chief Financial Officer, Gülsen Kama, was impacted and Ms. Kama will no longer be employed with the Company effective September 18, 2024.
Mark Adamchak, Vice President of Accounting & Finance was appointed to serve as the principal accounting officer of the Company, effective September 18, 2024.
On August 14, 2023, the Company announced the appointment of Gülsen Kama as Bionano Genomics, Inc.’s (the “Company”) Chief Financial Officer, effective as of September 11, 2023
On August 11, 2023, Christopher Stewart resigned as Chief Financial Officer of the Company effective as of September 11, 2023
On November 14, 2022, Richard Shippy resigned from his position as Chief Business Officer of Bionano Genomics, Inc., effective immediately.
the Board appointed Aleksandar Rajkovic, M.D., Ph.D. as a Class III director, effective as of such date
On December 21, 2021, the Board appointed Vincent J. Wong as a Class I director, effective as of such date, to serve in such capacity until the Company’s 2022 annual meeting of stockholders.
Max materiality 0.85 · Median 0.70 · Most common event other_material